
Motohiro Shindo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9988744/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial. Lancet Haematology,the, 2020, 7, e218-e225.	4.6	65
2	Reticulocyte hemoglobin equivalent as a potential marker for diagnosis of iron deficiency. International Journal of Hematology, 2017, 106, 116-125.	1.6	43
3	Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronicâ€phase chronic myeloid leukemia. European Journal of Haematology, 2018, 101, 95-105.	2.2	18
4	Non-transferrin-bound iron assay system utilizing a conventional automated analyzer. Clinica Chimica Acta, 2014, 437, 129-135.	1.1	16
5	A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia/Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 23-30.e2.	0.4	15
6	Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and Sézary syndrome. Hematological Oncology, 2020, 38, 266-271.	1.7	14
7	Loss of ABCB7 gene: pathogenesis of mitochondrial iron accumulation in erythroblasts in refractory anemia with ringed sideroblast with isodicentric (X)(q13). International Journal of Hematology, 2011, 93, 311-318.	1.6	12
8	Iron-induced epigenetic abnormalities of mouse bone marrow through aberrant activation of aconitase and isocitrate dehydrogenase. International Journal of Hematology, 2016, 104, 491-501.	1.6	10
9	A nationwide survey of hypoplastic myelodysplastic syndrome (a multicenter retrospective study). American Journal of Hematology, 2017, 92, 1324-1332.	4.1	9
10	Rapid reduction in <i><scp>BCR</scp>â€<scp>ABL</scp>1</i> transcript predicts deep molecular response in dasatinibâ€treated chronicâ€phase chronic myeloid leukaemia patients. European Journal of Haematology, 2018, 100, 27-35.	2.2	9
11	Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report. American Journal of Kidney Diseases, 2019, 74, 844-848.	1.9	9
12	Successful outcome with reduced-intensity condition regimen followed by allogeneic hematopoietic stem cell transplantation for relapsed or refractory anaplastic large-cell lymphoma. International Journal of Hematology, 2019, 110, 723-728.	1.6	9
13	In vivo behavior of NTBI revealed by automated quantification system. International Journal of Hematology, 2016, 104, 175-181.	1.6	8
14	Pazopanib-induced Endothelial Injury with Podocyte Changes. Internal Medicine, 2018, 57, 987-991.	0.7	8
15	Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia. Case Reports in Hematology, 2012, 2012, 1-2.	0.4	6
16	Pretreatment evaluation of fluorescence resonance energy transferâ€based drug sensitivity test for patients with chronic myelogenous leukemia treated with dasatinib. Cancer Science, 2018, 109, 2256-2265.	3.9	5
17	Centrally administered orexin prevents lipopolysaccharide and colchicine induced lethality via the vagal cholinergic pathway in a sepsis model in rats. Biochemical Pharmacology, 2020, 182, 114262.	4.4	5
18	Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test. International Journal of Hematology, 2019, 110, 482-489.	1.6	4

MOTOHIRO SHINDO

#	Article	IF	CITATIONS
19	Successful Treatment of Myeloid Sarcoma in an Elderly Patient with Myelodysplastic Syndrome with Reduced-Dose Azacitidine. Case Reports in Hematology, 2021, 2021, 1-8.	0.4	3
20	Development of POEMS syndrome after an initial manifestation of solitary plasmacytoma. International Journal of Hematology, 2011, 93, 815-821.	1.6	2
21	A selective splicing variant of hepcidin mRNA in hepatocellular carcinoma cell lines. Biochemical and Biophysical Research Communications, 2016, 476, 501-507.	2.1	2
22	Pseudogout Attack after Pegfilgrastim Administration in Anaplastic Large Cell Lymphoma. Internal Medicine, 2018, 57, 1779-1782.	0.7	2
23	Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection. Medicine (United States), 2022, 101, e29055.	1.0	2
24	The treatment choices and outcome of hepatocellular carcinoma in hemophilic patients with human immunodeficiency virus/hepatitis C virus (HIV/HCV) coinfection due to contaminated blood products in Japan. Journal of Gastrointestinal Oncology, 2021, 12, 2952-2959.	1.4	2
25	Hepatitis B virus (HBV) reactivation in an acute lymphoblastic leukemia patient despite being vaccinated against HBV in infancy. Digestive and Liver Disease, 2019, 51, 1487-1488.	0.9	1
26	Acquired hemophilia A associated with Epstein–Barr-virus-associated T/natural killer-cell lymphoproliferative disease. Medicine (United States), 2021, 100, e25518.	1.0	1
27	Direct Upregulation of Iron Regulatory Hormone Hepcidin by Interferon Alpha. Blood, 2011, 118, 2103-2103.	1.4	0
28	Velocity of Early BCR-ABL Transcript Elimination As an Optimized Predictor of Deep Molecular Response in Chronic Myeloid Leukemia Patients in Chronic Phase on Treatment with Dasatinib. Blood, 2015, 126, 4052-4052.	1.4	0